ASLT: A Potential Drug Target for Neurological Disorders (P45102)

Target Name: Arylsulfatase

NCBI ID: P45102

Arylsulfatase

Other Name(s): Cerebroside-sulfatase | Sulfatase | Nitrocatechol sulfatase

ASLT: A Potential Drug Target for Neurological Disorders

Arylsulfatase (nonspecified subtype) (Cerebroside-sulfatase), also known as ASLT or Cephosulfatase, is an enzyme located in various tissues of the body that plays a crucial role in the breakdown of neurotransmitters, such as dopamine, serotonin, and GABA. This enzyme is a key player in the neurotransmitter clearance process and its dysfunction has been implicated in various neurological disorders, including Parkinson's disease, addiction, and neurodegenerative diseases.

ASLT is a potent enzyme that converts the neurotransmitter substrates into their respective neurotransmitter products, by breaking down the ester bonds between the substrate and the phospholipid molecule. This process is critical for the efficient elimination of neurotransmitters from the axon terminal, where they are involved in transmitting signals between neurons. The breakdown of neurotransmitters by ASLT is highly specific, and the enzyme is known to have a preferential preference for certain neurotransmitters over others.

ASLT has been shown to be involved in various neurological disorders, including Parkinson's disease, addiction, and neurodegenerative diseases. In Parkinson's disease, ASLT has been found to be decreased in the brains of individuals with the disease, and ASLT has been shown to play a protective role in the disease by breaking down neurotransmitters that are thought to contribute to the progression of the disease. Similarly, in addiction, ASLT has been shown to be involved in the neurotransmitter systems of the brain and has been implicated in the development of addiction.

ASLT has also been shown to be involved in the pathophysiology of neurodegenerative diseases, such as Alzheimer's disease and Huntington's disease. In these diseases, ASLT is thought to contribute to the breakdown of neurotransmitters and the formation of neuroinclusions, which are thought to play a role in the progression of these diseases.

ASLT is a potential drug target for the treatment of various neurological disorders, including Parkinson's disease, addiction, and neurodegenerative diseases. By inhibiting ASLT, researchers hope to reduce the production of neurotransmitters that contribute to the progression of these diseases. Additionally, by increasing ASLT levels, researchers hope to protect against the development of these diseases and potentially reverse their progression.

In conclusion, Arylsulfatase (nonspecified subtype) (Cerebroside-sulfatase) is an enzyme that plays a crucial role in the breakdown of neurotransmitters and its dysfunction has been implicated in various neurological disorders. ASLT has been shown to be involved in the development and progression of Parkinson's disease, addiction, and neurodegenerative diseases. Therefore, ASLT is a potential drug target for the treatment of these disorders and a promising area of research in the field of neuroscience.

Protein Name: Arylsulfatase (nonspecified Subtype)

The "Arylsulfatase Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Arylsulfatase comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets